Genetic Risk Score of 46 Type 2 Diabetes Risk Variants Associates With Changes in Plasma Glucose and Estimates of Pancreatic beta-Cell Function Over 5 Years of Follow-Up by Andersson, E. A. et al.
Genetic Risk Score of 46 Type 2 Diabetes Risk Variants
Associates With Changes in Plasma Glucose and
Estimates of Pancreatic b-Cell Function Over
5 Years of Follow-Up
Ehm A. Andersson,1 Kristine H. Allin,1 Camilla H. Sandholt,1 Anders Borglykke,2 Cathrine J. Lau,2
Rasmus Ribel-Madsen,1 Thomas Sparsø,1 Johanne M. Justesen,1 Marie N. Harder,1 Marit E. Jørgensen,3
Torben Jørgensen,2,4,5 Torben Hansen,1,6 and Oluf Pedersen1,3,7
More than 40 genetic risk variants for type 2 diabetes have been
validated. We aimed to test whether a genetic risk score associates
with the incidence of type 2 diabetes and with 5-year changes in
glycemic traits and whether the effects were modulated by changes
in BMI and lifestyle. The Inter99 study population was genotyped for
46 variants, and a genetic risk score was constructed. During
a median follow-up of 11 years, 327 of 5,850 individuals developed
diabetes. Physical examinations and oral glucose tolerance tests
were performed at baseline and after 5 years (n = 3,727). The risk of
incident type 2 diabetes was increased with a hazard ratio of 1.06
(95% CI 1.03–1.08) per risk allele. While the population in general
had improved glucose regulation during the 5-year follow-up period,
each additional allele in the genetic risk score was associated with
a relative increase in fasting, 30-min, and 120-min plasma glucose
values and a relative decrease in measures of b-cell function over
the 5-year period, whereas indices of insulin sensitivity were un-
affected. The effect of the genetic risk score on 5-year changes in
fasting plasma glucose was stronger in individuals who increased
their BMI. In conclusion, a genetic risk score based on 46 variants
associated strongly with incident type 2 diabetes and 5-year changes
in plasma glucose and b-cell function. Individuals who gain weight
may be more susceptible to the cumulative impact of type 2 diabe-
tes risk variants on fasting plasma glucose. Diabetes 62:3610–
3617, 2013
Type 2 diabetes is a complex metabolic disorderwhere both environment and genetic dispositionact in concert to cause the disease. Over the lastfew years, genome-wide association studies and
large-scale genotyping studies using the Metabochip array
have identiﬁed close to 50 variants associating with type 2
diabetes in cross-sectional studies of whites (1 [rev. in 2]).
The vast majority of genetic association studies have
been performed in a cross-sectional study design. In cross-
sectional studies, only a snapshot of the effect can be
evaluated, and it is not clear from these studies to what
extent the genetic risk variants may affect changes over
time. It is of relevance to address the ﬂuctuations in gly-
cemic traits in order to obtain improved understanding of
the timing and cause of progression toward disease.
Whereas recent prospective studies in populations of vary-
ing age, metabolic status, and ethnicity have shown that
genetic risk is associated with incidence of type 2 diabetes
(3–8), very few studies have investigated the effect of ge-
netic variants on changes in quantitative glycemic traits
over time in large study samples (3,9–11). How changes in
BMI and lifestyle may interact with genetic factors to
modify glucose homeostasis over time has, moreover, been
even less investigated (6,12). Since the effects of common
single variants are generally modest and of limited clinical
signiﬁcance, it is more likely that risk assessment of
a combination of variants will be useful to identify sub-
groups at increased risk of type 2 diabetes that would re-
quire more aggressive intervention and monitoring.
In the current study of the Danish population-based
Inter99 study sample, we aimed to investigate 1) the asso-
ciation between a genetic risk score of 46 validated type 2
diabetes risk variants and the incidence of type 2 diabetes,
2) the association between the genetic risk score and
changes in oral glucose tolerance test (OGTT)-derived gly-
cemic traits over 5 years, and 3) whether speciﬁc changes
in BMI and lifestyle factors, including smoking, physical
activity, and diet, may interact with the effect of the genetic
risk score on observed changes in glycemic traits.
RESEARCH DESIGN AND METHODS
Inter99 study population. The Inter99 study (clinical trial reg. no.
NCT00289237, clinicaltrials.gov) is a population-based nonpharmacological
intervention study for ischemic heart disease conducted at the Research Centre
for Prevention and Health in Glostrup, Denmark (www.inter99.dk). A ran-
domized sample of 13,016 individuals living in Copenhagen County (30–60
years) was drawn from the Civil Registration System and further pre-
randomized into high-intensity (90%) and low-intensity (10%) intervention
groups. A total of 6,784 (52%) subjects attended the baseline health exami-
nation (median age 45 years). All participants received individual lifestyle
counseling at the baseline examination, focused on habits of smoking, phys-
ical activity, dietary intake, and use of alcohol. The high-intensity group was in
addition offered group-based lifestyle counseling if considered at high risk for
ischemic heart disease. Follow-up examinations were conducted after 5 years
with a participation rate of 66% (n = 4,511) (13–15).
Incident type 2 diabetes. A ﬂowchart of the current study is shown in Fig. 1.
Information on incident type 2 diabetes was collected from the Danish Na-
tional Diabetes Register (16). Information included date of inclusion and
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criteria for inclusion. Data until 31 December 2010 were available. Information
on death and emigration was obtained from the Danish Central Person Reg-
ister until 31 December 2010.
Anthropometrics, biochemical measurements, and lifestyle factors. At
the baseline and 5-year follow-up examination, anthropometric and biochemical
measures were obtained after an overnight fast. Weight (kilograms) and height
(centimeters) were measured in light indoor clothes and without shoes. All
participants without previously diagnosed diabetes were characterized by
a standardized 75-g OGTT with plasma glucose and serum insulin measured at
fasting and 30 and 120 min after the oral glucose load. Plasma glucose was
analyzed using the hexokinase/glucose-6-phosphate dehydrogenase technique
(Boehringer Mannheim, Germany), which has an intra-assay precision of co-
efﬁcient of variation (CV) 1.1% and an interassay precision of CV 2.3%. Serum
insulin (excluding des-31,32 and intact proinsulin) was measured using the
AutoDELFIA insulin kit (Perkin-Elmer/Wallac, Turku, Finland), with an inter-
assay precision of CV ,6%. The conditions under which plasma glucose and
serum insulin were measured were identical at baseline and at the 5-year follow-
up examination.
Screen-detected diabetes was deﬁned according to World Health Organi-
zation 1999 criteria (17). All lifestyle factors were estimated from self-reported
questionnaire data as previously described (18–20). Written informed consent
was obtained from all participants. The study was approved by the regional
ethics committee of Copenhagen and is in accordance with the principles of
the Declaration of Helsinki II.
Genotyping. Genotyping was performed with the Metabochip (21) using the
Illumina HiScan (Illumina, San Diego, CA). Genotypes were called using the
genotyping module (version 1.9.4) of GenomeStudio software (version 2011.1;
Illumina), and custom cluster data generated from ;6,000 Danish DNA samples
were analyzed on the same Illumina HiScan. Quality control removed 1st- and
2nd-degree related individuals (n = 119), individuals with an extreme inbreeding
coefﬁcient (F. 0.1 or F, 0.1, n = 25), individuals with a low genotype call rate
(call rate ,90%, n = 30), individuals with mislabeled sex (n = 11), and indi-
viduals with a high discordance rate to previously genotyped single nucleotide
polymorphisms (concordance ,80%, n = 65), leaving 6,127 individuals who
passed all quality-control criteria. The average call rate for all SNPs on the
Metabochip was 99.0%. Of the previously identiﬁed type 2 diabetes risk variants,
ﬁve were not present on the Metabochip and did not have perfect proxies, and
thus, these were genotyped by KASPar (KBioscience, Hoddesdon, U.K.) with
success rates .96% and error rates ,0.5%. All variants obeyed Hardy-Weinberg
equilibrium (P . 0.01), except HMGA2, rs1531343 (P = 0.0043). An overview of
the 46 variants genotyped is provided in Supplementary Table 1. The 46 variants
were chosen based on genome-wide signiﬁcant (P , 5 3 1028) association
signals for the risk of type 2 diabetes identiﬁed or conﬁrmed in European
populations. Variants only found to be associated with type 2 diabetes in Asian
populations were not included. The risk variant in DUSP is not included in the
current study because of the location on the X-chromosome. Variants in or near
FTO and MC4R were not included owing to a primary effect on obesity.
Genetic risk score. Individuals with more than two missing genotypes were
excluded (n = 146). For individuals with one (n = 588) or two (n = 109) missing
genotypes, genotypes were imputed by assigning the most common genotype in
Inter99 for the missing variants. A simple genetic risk score was constructed by
summing up the number of risk alleles over 46 variants for each individual. The
median risk score was 50, ranging from 31 to 66. A weighted genetic risk score
was created as previously described (22) and by weighting each risk allele with
the effect size (the natural log of the odds ratios) for risk of type 2 diabetes
reported by the largest meta-analyses performed (1). Effect sizes used for
weighting for the speciﬁc variants or the best proxies can be seen in Supple-
mentary Table 1. All results are from analyses of the simple genetic risk score.
The weighted genetic risk score was used to check whether weighting each
allele would change the results obtained for the simple risk score.
Statistical analyses.Data were analyzed using the STATA statistical software
(version 12.1; StataCorp, College Station, TX) and RGui, version 2.13.2 (http://
www.r-project.org/). The Kaplan-Meier method was used to plot cumulative
incidence of type 2 diabetes against age, and the log-rank trend test was used
to test for differences between tertiles of the genetic risk score. Cox pro-
portional hazards regression models were used to address the risk of incident
type 2 diabetes. Individuals with self-reported diabetes at the baseline exam-
ination as well as individuals present in the Danish National Diabetes Registry
before the baseline examination were excluded from the present analyses of
incident type 2 diabetes. To automatically adjust for age, we used left trun-
cation and age as a time scale. We tested the assumption of proportional
hazards graphically by plotting log(cumulative hazard) as a function of age
and with a test based on Schoenfeld residuals. We detected no major viola-
tions of the proportional hazards assumption.
Paired t tests were used to test for differences in quantitative traits at baseline
and at follow-up. Linear regression was used to model the effect of the genetic
risk score on 5-year changes in glycemic traits. Individuals with known diabetes
at the baseline or at the follow-up examination were excluded from the present
analyses of glycemic traits. Values of plasma glucose, serum insulin, and all in-
dices were logarithmically transformed before analyses to obtain a normal dis-
tribution. Changes in lifestyle measures of physical activity, smoking, and diet
were individually deﬁned into three classes; healthier, unhealthier, or no change.
The fully adjusted regression model included the additive genetic risk score,
baseline age, sex, baseline BMI, change in BMI, and baseline value of the trait
analyzed.
5-year outcome ¼ b0 þ b1 riskþ b2 ageþ b3 sexþ b4baseline BMI
þ b5 DBMIþ b6 baseline value of outcome variable
Additive interactions between the genetic risk score and changes in BMI and
changes in lifestyle factors (physical activity, diet, and smoking) were tested by
including the interaction term “change in BMI3 risk score” or “change in lifestyle
factor 3 risk score,” where BMI change is a continuous variable and change of
lifestyle is a three-class variable, into the fully adjusted regression model.
5-year outcome ¼ b0 þ b1 riskþ b2 ageþ b3 sexþ b4 baseline BMI
þ b5 DBMIþ b6 baseline value of outcome variable
þ b7 risk 3 DBMI
or
5-year outcome ¼ b0 þ b1 riskþ b2 ageþ b3 sexþ b4 baseline BMI
þ b5 DBMIþ b6 Dlifestyle
þ b7 baseline value of outcome variable
þ b8 risk 3 Dlifestyle
FIG. 1. Flowchart over the number of study participants of the current study.
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RESULTS
Incidence of diabetes. A total of 5,850 individuals had
information on the genetic risk score and did not have
known diabetes at the baseline examination. These indi-
viduals were followed with a median follow-up time of 11
years, and 327 individuals developed type 2 diabetes. The
genetic risk score was strongly associated with incident
diabetes (Fig. 2 and Table 1). The cumulative incidence of
type 2 diabetes as a function of age increased with tertiles
of the genetic risk score (log-rank trend test, P = 0.0004)
(Fig. 2). Each additional allele increased the risk of type 2
diabetes with a multifactor-adjusted hazard ratio of 1.06
(95% CI 1.03–1.09, P = 1.1 3 1024) (Table 1). To elucidate
differential effects over age, we stratiﬁed the population
into two age-groups; below or above 50 years of age at
censoring. In a Cox regression model adjusted for age, sex,
and BMI, the hazard ratio was 1.10 (95% CI 1.04–1.16) in
individuals age ,50 years, while it was 1.06 (95% CI 1.02–
1.09) in individuals .50 years. No interaction with age-
group was observed (P = 0.19).
Five-year changes in quantitative glycemic traits. To
address the underlying phenotypes causing the increased
risk of diabetes, we tested whether the genetic risk score
had measureable effects on changes in quantitative gly-
cemic traits during the 5 years of follow-up. A total of 3,727
had information on the genetic risk score and did not have
known diabetes at the baseline or at the follow-up exam-
ination. On average, after 5 years the population had im-
proved glycemic regulation (15). They experienced an
average decrease in fasting, 30-min, and 120-min plasma
glucose values, as well as in fasting serum insulin values.
They were less insulin resistant and increased their dis-
position index, although there was an average weight gain
in the population. A borderline improvement of corrected
insulin response occurred, but no changes in the insuli-
nogenic index were observed (Table 2).
In the fully adjusted model, each additional allele in the
genetic risk score associated with a relative increase in
plasma glucose at fasting and during an OGTT over the
5-year follow-up period (Table 3). Moreover, the genetic
risk score associated with relative decrements in insuli-
nogenic index, corrected insulin response, and disposi-
tion indices—all surrogate measures of pancreatic b-cell
function. No associations with changes in values of serum
insulin or indices of insulin sensitivity were observed
(Table 3). Similar results were seen when changes in life-
style factors were included in the regression model (data
not shown). Although the genetic risk score associated with
increases in plasma glucose per allele, the average indi-
vidual still had levels lower over the 5-year period. Con-
sequently, individuals at increasingly higher genetic risk
improved their plasma glucose values less compared with
individuals with a lower genetic risk.
When subgroups of upper versus lower decile of genetic
risk were compared, the difference evolving over the 5-year
period between these two groups was 2.3% for fasting
plasma glucose, which on average corresponds to ;0.14
mmol/L. With these results extrapolated to a follow-up time
of 20 years (representing an average year span in Inter99
from 45 to 65 years of age) and with linearity assumed in the
genetic effects over the 20 years, this would correspond
to a difference between the groups of ;0.54 mmol/L for
fasting plasma glucose. For comparison, the effect of a one-
unit BMI increase over 5 years is associated with a 1%
(;0.05 mmol/L) relative increase in fasting plasma glu-
cose in this population.
To understand the effect of adding more risk variants to
the genetic risk score, we calculated the effect of a genetic
risk score comprising 15 variants overlapping the study
by Lyssenko et al. (3). When we included only these 15
variants in the genetic risk score, the effect on changes
in fasting plasma glucose was 0.22% (95% CI 0.11–0.32,
P = 1 3 1024 per allele) compared with a per allele effect
of 0.18% (95% CI 0.12–0.24, P = 9 3 1029) when including
46 variants in the genetic risk score. Based on the estimated
effect sizes and the number of variants included in two
genetic risk scores, a theoretical maximum difference be-
tween individuals carrying no risk alleles and individuals
FIG. 2. Plot showing the cumulative incidence of type 2 diabetes for tertiles of the genetic risk score (median follow-up 11 years). The ﬁrst tertile
is low genetic risk, and the third is high genetic risk. (n = 5,850, cases = 327.)
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carrying the maximum number of risk alleles (30 or 92) was
calculated for changes in fasting plasma glucose. This cor-
responded to a theoretical maximum change of ;7% for the
risk score comprising 15 variants and ;17% for the updated
score comprising 46 variants.
Interactions between genetic risk score and changes
in BMI and lifestyle factors. For exploration of whether
the effect of the genetic risk score on changes in glycemic
traits was affected by changes in BMI or lifestyle factors,
we tested for potential interactions. Since the genetic risk
score had the strongest statistical association with fasting
plasma glucose, potential interactions were only assessed
for this outcome to achieve the highest statistical power.
We found an interaction between the genetic risk score
and BMI changes over 5 years in relation to changes in
fasting plasma glucose (P = 0.004). An increased BMI over
the 5-year period resulted in a larger effect of the genetic
risk score on changes in fasting plasma glucose (Fig. 3).
Individuals who gained weight and who were in the highest
tertile of genetic risk on average increased their unadjusted
fasting plasma glucose values by 0.19%, whereas individuals
who lost weight (or were weight stabile) and belonged to
the lowest tertile of genetic risk on average decreased their
unadjusted fasting plasma glucose by 23.3% over 5 years
(Fig. 3A). When dividing the population into quartiles of
BMI change, we observed a stepwise increasing effect of
TABLE 1
Associations between the genetic risk score and the risk of incident late-onset diabetes in the Inter99 cohort (median follow-up time 11
years) (n = 5,850)
Model 1 Model 2 Model 3
Hazard ratio per risk allele (95% CI) 1.06 (1.03–1.08) 1.06 (1.03–1.09) 1.06 (1.03–1.09)
P 5 3 1025 9 3 1026 1 3 1024
Data are hazard ratios per risk allele and P values of three different models. All models are adjusted for age using left truncation and age as
time scale. Three models were analyzed: model 1, a simple model including only the genetic risk score, sex, and age; model 2, a model
including genetic risk score, sex, age, and baseline BMI; model 3, a fully adjusted model including genetic risk score, sex, age, baseline BMI,
baseline smoking habits, baseline measure of physical activity, and baseline measure of diet.
TABLE 2
Overview of the average changes from baseline to 5-year follow-up examinations in the Inter99 cohort (n = 3,727)
Change from baseline
to follow-up
P for change from baseline
to follow-up
Participants (n) 3,727
BMI (kg/m2) 0.42 (0.36–0.48) 1 3 10245
Fasting glucose (mmol/L) 20.08 (20.09 to 20.06) 3 3 10224
30-min glucose (mmol/L) 20.02 (20.08 to 0.03) 0.3
120-min glucose (mmol/L) 20.13 (20.19 to 20.08) 1 3 1026
Fasting insulin (%) 28 (29 to 26) 2 3 10216
30-min insulin (%) 2 (1–4) 0.009
120-min insulin (%) 6 (3–8) 2 3 1026
HOMA index of insulin resistance (%) 29 (212 to 27) 2 3 10220
Matsuda index of insulin sensitivity (%) 3 (1–4) 0.002
Corrected insulin response (%) 2 (0–5) 0.04
Insulinogenic index (%) 1 (21 to 3) 0.4
Disposition index 1 (%) 8 (6–12) 4 3 10210
Disposition index 2 (%) 5 (3–8) 5 3 1025
Weight loss/gain (n)
Weight gain 2,286
Weight loss (or stable) 1,441
Physical activity (n)
Less active 877
No change 1,748
More active 831
Dietary score (n)
Unhealthier diet 366
No change 2,297
Healthier diet 912
Smoking (n)
More intensive smoking 119
No change 3,199
Less intensive smoking or cessation 383
Data are means (95% CI) unless otherwise indicated. Data are presented for individuals with information on genetic risk who participated in
both baseline and follow-up examinations after exclusion of individuals with known diabetes. Paired t tests were used to test for differences in
quantitative traits at baseline and at follow-up. Values of serum insulin and derived indices were logarithmically transformed, and the change
is shown on the log scale.
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the genetic risk score with higher quartiles of BMI change in
the fully adjusted model (Fig. 3B).
No interactions between the genetic risk score or
changes in smoking, physical activity, or diet were ob-
served (P = 0.20–0.44). Throughout all analyses, similar
results were obtained for the weighted genetic risk score
(data not shown).
DISCUSSION
In the current study, we have performed prospective
analyses of a genetic risk score comprising 46 genetic risk
variants for type 2 diabetes in the Danish Inter99 pop-
ulation of middle-aged to elderly people without ac-
counting for single variant associations or gene-gene
interactions.
TABLE 3
Associations between the genetic risk score and changes in glycemic traits obtained during OGTTs in the Inter99 cohort (n = 3,727)
Effect per risk allele % (95% CI) P
Changes in plasma glucose
Fasting 0.18 (0.12–0.24) 9 3 1029
30 min 0.31 (0.19–0.44) 5 3 1027
120 min 0.39 (0.20–0.58) 6 3 1025
Changes in serum insulin
Fasting 0.04 (20.29 to 0.36) 0.8
30 min 20.36 (20.72 to 0.00) 0.05
120 min 0.14 (20.36 to 0.63) 0.6
Changes in measures of b-cell function
Insulinogenic index 20.92 (21.4 to 20.43) 3 3 1024
Corrected insulin response 21.2 (21.7 to 20.77) 2 3 1027
Changes in measures of insulin sensitivity
HOMA index of insulin resistance 0.23 (20.12 to 0.58) 0.2
Matsuda index of insulin sensitivity 20.09 (20.42 to 0.24) 0.6
Changes in disposition indices
Disposition index 1 21.3 (21.8 to 20.68) 2 3 1025
Disposition index 2 21.4 (22.0 to 20.89) 2 3 1027
All traits were logarithmically transformed before analyses, and effects sizes are given in %. All analyses were adjusted for sex, baseline age,
baseline BMI, change in BMI, and baseline value of the trait analyzed (logarithmically transformed). Insulinogenic index was calculated as
follows: (serum insulin at 30 min 2 fasting serum insulin)/(plasma glucose at 30 min 2 fasting plasma glucose). Corrected insulin response
was calculated as follows: (100 3 serum insulin at 30 min)/[plasma glucose at 30 min 3 (plasma glucose at 30 min 2 3.89)]. Homeostasis
model assessment index of insulin resistance was calculated as follows: [(fasting plasma glucose 3 fasting serum insulin)/135]. Matsuda index
of insulin sensitivity was calculated as {10,000/=[(fasting plasma glucose 3 fasting serum insulin) 3 (mean plasma glucose 3 mean serum
insulin during OGTT)]}. Disposition index 1 was calculated as insulinogenic index/homeostasis model assessment (HOMA) of insulin re-
sistance. Disposition index 2 was calculated as corrected insulin response 3 Matsuda index of insulin sensitivity.
FIG. 3. Interaction between the genetic risk score and BMI change on changes in fasting plasma glucose over 5 years. A: The effect of tertiles of the
genetic risk score are given on changes in fasting plasma glucose in individuals who gained weight (n = 2,286) and in individuals who lost weight or
were weight stable (n = 1,441) over 5 years. The ﬁrst tertile is low genetic risk, and the third is high genetic risk. B: The effect sizes and 95% CIs
per allele of the genetic risk score on changes in fasting plasma glucose in the fully adjusted model are shown for different quartiles of BMI changes
in the population (n = 3,727).
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In line with previous studies, we found that an updated
genetic risk score was strongly associated with incident
type 2 diabetes (3–8), although effect sizes were modest.
What is new, we found that in the Inter99 population the
genetic risk score had measureable effects on changes in
plasma glucose and estimates of pancreatic b-cell function
during 5 years of follow-up. Of interest, we report an in-
teraction suggesting that individuals increasing their BMI
are more susceptible to the effect of the genetic risk.
Incident diabetes. Our reported hazard ratio of 1.06 per
allele resides in the lower end of the spectrum previously
reported (3–8). One explanation may be that Inter99 is
a lifestyle intervention study and it has been suggested that
lifestyle intervention may attenuate the effect of genetic
risk. This has been seen particularly for the variant in
TCF7L2 in the Diabetes Prevention Program (23) and
Finnish Diabetes Prevention Study (24) and was also
suggested when a genetic risk score of 34 variants was
investigated (6). Longer follow-up times have also been
suggested to increase the effect of genetic variants.
Moreover, it has recently been observed that the effects of
genetic variants are stronger with younger age (,50 years)
(5). When stratifying our study population into age-groups
below or above 50 years, we observed a higher hazard
ratio in the younger group, thus suggesting that also in
Inter99 the genetic risk of type 2 diabetes may be slightly
stronger with younger age onset; however, there was no
signiﬁcant interaction.
A number of reports have lately addressed the predictive
ability of genetic risk scores in the progression to type 2
diabetes and collectively conclude that genetic risk
assessment at best modestly improves prediction and
reclassiﬁcation over conventional risk factors such as age,
BMI, and family history (3–8). Some of these reports have
longer follow-up times and include more individuals than
our study, and thus, it was not in the scope of the current
study to investigate this further.
Five-year changes in quantitative glycemic traits. It
was not known whether an updated genetic risk score of
46 type 2 diabetes risk variants would affect changes in
glycemic traits during 5 years of follow-up or how the
genetic risk may interact with changes in BMI and lifestyle
factors. A previous study in the Botnia cohort including
2,444 Scandinavian individuals evaluated the effect of
a genetic risk score, comprising 16 type 2 diabetes risk
variants, on changes in OGTT-derived glycemic measures
during 8 years of follow-up. The authors found that this
genetic risk score associated with decreased insulin se-
cretion and disposition index, whereas it did not affect
changes in insulin sensitivity over time (3). In line with the
results from the Botnia study, we found that despite a
5-year lifestyle intervention a genetic risk score comprising
46 risk variants associated with 5-year changes in plasma
glucose and measures of b-cell function, but it did not
associate with changes in measures of insulin sensitivity.
In accordance with our results, the majority of variants
included in the risk score have in cross-sectional studies
been suggested to modulate the risk of type 2 diabetes
through b-cell dysfunction and not through insulin resis-
tance (rev. in 25).
The estimated per-allele effect size was slightly lower for
the genetic risk score based on all 46 variants compared
with a risk score based on only 15 variants from the study
by Lyssenko et al. (3), while the theoretical difference in
change in fasting plasma glucose between individuals
carrying no risk alleles and maximal number of risk alleles
was notably larger for the risk score based on all 46 var-
iants. Together, these results suggest that inclusion of
more risk variants with relatively lower individual effect
sizes observed at the cross-sectional level does not infer
uncertainty in the statistical models but strengthens the
association between a genetic risk score and changes in
fasting plasma glucose.
A recent study using the Whitehall II population reported
that a genetic risk score of six variants associating with
2-h glucose values had a stronger impact on levels of 2-h
glucose with increasing age, while a genetic risk score of
16 fasting plasma glucose variants had constant effects on
fasting plasma glucose over the age span investigated (11).
In the current study, we did not ﬁnd differential effects of
the genetic risk score on changes in fasting or 2-h plasma
glucose among different age-groups, and we did not dem-
onstrate any interactions with age (data not shown). Of
note, the Whitehall II study (11) evaluated variants spe-
ciﬁcally associated with fasting or 2-h glucose values in
nondiabetic individuals, which are only partially overlapping
those variants found to increase risk of type 2 diabetes in-
vestigated in the current study.
Interactions between genetic risk score and changes
in BMI and lifestyle factors.We observed an interaction
between the genetic risk score and changes in BMI, sug-
gesting that individuals increasing their BMI may be more
susceptible to the effects of type 2 diabetes risk variants.
From a different point of view, this suggests that weight
loss may attenuate the effect of the genetic risk, since the
genetic risk score had a smaller effect in the group of
individuals who decreased their BMI. Even though a large
part of the general population will beneﬁt from weight
loss, these results suggest that it may be a particularly
fruitful intervention for those at increased genetic risk of
type 2 diabetes. In line with this, a recent study reported
that intensive lifestyle intervention was effective in pre-
venting type 2 diabetes at any genetic risk but with sug-
gestive evidence that it may be more effective in the group
with highest genetic risk (6).
The inﬂuence of obesity on genetic risk of type 2 di-
abetes has been debated. A large genome-wide association
study stratifying lean and obese cases found that the ma-
jority of previously validated type 2 diabetes risk variants
had a higher risk estimate for type 2 diabetes among lean
case compared with obese case subjects (26). In contrast,
a smaller study suggested that a genetic risk score had
a stronger effect among obese participants (22), and it has
also been reported that the effect of a genetic risk score on
risk of impaired glucose tolerance was not evident in lean
or insulin-sensitive persons (27). These reported inter-
actions clearly illustrate the diversity underlying genetic
risk of complex type 2 diabetes, and further well-powered
studies investigating potential interactions are highly
warranted.
We were not able to show any interactions with changes
in lifestyle factors, which may be due to a modest statis-
tical power to exploit the potential modifying impact of
these factors. It is, however, likely that a large part of
lifestyle changes may be “summarized” in the BMI change,
thus explaining why BMI change may be a statistically
more powerful factor to include in the model.
Obesity is believed to contribute to the risk of type 2
diabetes through several mechanisms including insulin
resistance, inﬂammation, and lipotoxicity of the pancreatic
b-cells and other organs (28). It is not known which factors
may explain the interaction with the genetic risk observed
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in the current study; yet, a plausible explanation may be
that a high genetic risk of type 2 diabetes renders the
pancreatic b-cells more susceptible to an obesogenic en-
vironment.
Strengths and limitations. The major strengths of the
current study are as follows: 1) the longitudinal follow-up
in a large well-phenotyped homogenous cohort, 2) inves-
tigations of an updated list of type 2 diabetes risk variants
genotyped with good genotyping quality and state-of-the-art
quality control, and 3) the repeated examinations includ-
ing anthropometric measurements, OGTTs, and extensive
characterization of lifestyle, which provide a wide collec-
tion of glycemic traits and relevant modifying factors.
Since Inter99 is a lifestyle intervention study, it is not
known whether our results are directly transferrable to
other populations, and further evidence is highly war-
ranted. It has been described previously that in the Inter99
study, the intensity of the lifestyle intervention (high vs.
low intensity) did not have any differential effect on 5-year
changes in fasting plasma glucose (15), and we obtained
similar results when adjusting for prerandomized in-
tervention groups in the current study (data not shown).
Interestingly, the group of individuals attending the follow-
up examination overall improved their glycemic regula-
tion, although their body weight increased. This seems to
contrast with results in previous studies. Nonetheless, the
group of individuals belonging to the highest tertile of
genetic risk and who also gained weight did increase their
values of plasma glucose over 5 years (fasting plasma
glucose, 0.02 mmol/L; 2-h glucose, 0.14 mmol/L). The
general glycemic improvement may be caused by enroll-
ment in the Inter99 intervention study itself, and attendees
for follow-up may also be those most motivated for im-
provement of their lifestyle (15). An alternative explanation
may be that unidentiﬁed bias has skewed the distribution
from the baseline to 5-year examination. This will, however,
not affect the validity of our results, as the genotypic dis-
tribution can be assumed to be random over such potential
bias, and our results are in line with those observed in the
study by Lyssenko et al. (3).
In conclusion, a genetic risk score comprising 46 type 2
diabetes risk variants associated strongly with incident
type 2 diabetes, changes in plasma glucose, and estimates
of pancreatic b-cell function over a 5-year period in the
Inter99 population of middle-aged to elderly Danish peo-
ple. Individuals who increased their BMI were more sus-
ceptible to the cumulative impact of risk variants on
fasting plasma glucose. This suggests that especially indi-
viduals at high genetic risk may beneﬁt from weight loss
intervention; however, this hypothesis remains to be
tested.
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